Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes (y 2)

Alkermes, Inc. is a biotechnology company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. The Company has two commercial products and a pipeline of extended-release injectable products and pulmonary products based on its proprietary technology and expertise. The Company's headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

This press release contains forward-looking statements, which involve risks and uncertainties within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are neither promises nor guarantees, and the businesses of Lilly, Amylin, and Alkermes are subject to significant risks and uncertainties. Actual results may differ materially from the forward-looking statements discussed in this press release. These forward-looking statements include risks and uncertainties, including but not limited to, that current or future clinical trials will not confirm previous results; risks and uncertainties that Amylin will be able to complete manufacturing scale-up and construction and validation of its manufacturing facility on a timely basis, or at all; risks and uncertainties inherent in the collaboration with and dependence upon Lilly, Amylin and/or Alkermes; risks and uncertainties regarding the drug discovery and development process, including whether exenatide LAR will receive regulatory approvals, be commercialized or prove to be commercially successful. These and additional risks and uncertainties are described more fully in Lilly, Amylin, and Alkermes' filings with the United States Securities and Exchange Commission, including their recently filed Form 10-Qs. The parties disclaim any obligation to update forward-looking statements.

P--LLY

REFERENCES

(1) Kolterman, O, Buse J, Fineman M, Gaines E, Heintz S, Bicsak T, Taylor K, Kim D, Aisporna M, Wang Y, Baron A. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting glucose in subjects with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2003; 88(7):3082-3089.

(2) The International Diabetes Federation Diabetes Atlas. Available at: http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-8.... Accessed April 12, 2005.

(3) The International Diabetes Federation, Prevalence / All diabetes. Available at http://www.eatlas.idf.org/Prevalence/All....

(4) Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281 (21):2005-2012.

(5) The International Diabetes Federation, Complications. Available at http://www.eatlas.idf.org/Complications/....

(6) The International Diabetes Federation, Diabetes Atlas, Second edition. The Economic Impact of Diabetes. 2003: 186.

    
    (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO
           http://www.newscom.com/cgi-bin/prnh/20060610/AMYLINLOGO
           http://www.newscom.com/cgi-bin/prnh/20050614/ALKSLOGO )

Lilly - Derin Denham, +1-317-277-6749 (office), +1-317-370-1435 (cell); Amylin - Alice Bahner, +1-858-642-7272 (office), +1-858-232-9072 (cell); Alkermes - Rebecca Peterson, +1-617-583-6378 (office), +1-617-899-2447 (cell). Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO ; http://www.newscom.com/cgi-bin/prnh/20060610/AMYLINLOGO ; http://www.newscom.com/cgi-bin/prnh/20050614/ALKSLOGO ; PRN Photo Desk, photodesk@prnewswire.com